- What are new features to the Enforcement Report?
- What is the Enforcement Report?
- What is a pending recall classification?
- How are recalls categorized in the Enforcement Reports?
- How else does FDA provide early notification about recalls?
- How do I subscribe to the Enforcement Report mailing list?
- What if I have additional questions about Enforcement Reports?
- Where do I find Additional Resources about Enforcement Reports?
As of July 24, 2018, the Enforcement Report now tracks and displays updates to a recall’s Classification, Reason for Recall, Code Information, and Product Description if changes occur after initial publication. This update history is available for all recalls posted or updated beginning July 24, 2018 and forward.
In addition, filtered navigation and location of search term are available in the Quick Search screen. The filtered navigation provide a means to further filter keyword results by categories such as Product Type, Recall Class, Status, and Recalling Firm. The location of term provides a snapshot of where the keyword or phrase is found in the recall.
Information for how these changes will appear and what parts of the Enforcement Report are effected can be found on the Enforcement Report New Features page.
All recalls monitored by FDA are included in the Enforcement Report once they are classified and may be listed prior to classification when FDA determines the firm’s removal or correction of a marketed product(s) meets the definition of a recall. Once FDA completes the hazard assessment, the Enforcement Report entry will be updated with the recall classification.
Instructions for navigating the report and definitions of the report contents are found on the Enforcement Report Navigation and Definitions page.
On June 15, 2017, as part of a larger effort to increase transparency, empower consumers, and enhance public health, the Enforcement Report began listing recalls pending classification, or “not yet classified” recalls, in addition to classified recalls, to alert the public sooner whenever a product has been recalled.
In these instances, the FDA has determined that a firm’s action meets the definition of a recall however the FDA has not completed its assessment of the hazard posed by the recalled product(s) yet – this is considered a pending classification. Once FDA completes the hazard assessment, the Enforcement Report entry will be updated with the recall classification (Class I, II or III) indicating the hazard posed by the recalled product(s). This initiative allows FDA to post certain recalls to the Enforcement Report sooner since the Agency is no longer waiting for the hazard assessment to be completed.
FDA considers a recall to be a firm's removal or correction of a marketed product that the FDA considers to be in violation of the laws it administers and against which the agency would initiate legal action. Separate from determining whether a firm’s action meets the definition of a recall, FDA also classifies a particular product recall to indicate the relative degree of health hazard (class I, II, or III) presented by the product being recalled. Recalls are categorized in the Enforcement Report as either class I, II, or III or "not yet classified."
FDA is conducting a trial pilot program to expedite notifications of Non-Blood (HCT/P, Vaccine, Derivative, etc.) product recalls to the public which can be found at Non-Blood Product On-Going Recalls.
To subscribe to the enforcement report mailing list please follow this link: Enforcement Report email subscription.
To subscribe to the Enforcement Report RSS feed to receive announcements for new weekly reports or updates to a previous weekly report, please use the following links:
Please e-mail firstname.lastname@example.org with any comments.
For information gathered from press releases and other public notices about certain recalls of FDA-regulated products, you can visit Recalls, Market Withdrawals, & Safety Alerts.
An additional enforcement tool is the Import Alert, which informs FDA field staff and the public that the agency has enough evidence to allow for Detention Without Physical Examination (DWPE) of products that appear to be in violation of FDA laws and regulations. More information can be found at Import Alerts.